http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018200597-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82b460ae2c0d553a2db7abd984e85631 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52 |
| filingDate | 2018-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_891d1d5afa418910a9f98698f07b8fc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfc72b3b0670225bce6b18ccf6bb9f95 |
| publicationDate | 2018-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2018200597-A1 |
| titleOfInvention | Ligands modified by circular permutation as agonists and antagonists |
| abstract | The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof. |
| priorityDate | 2012-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1094.